Taysha Gene Therapies (TSHA) Total Current Liabilities (2022 - 2025)
Historic Total Current Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $28.6 million.
- Taysha Gene Therapies' Total Current Liabilities fell 239.99% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year decrease of 239.99%. This contributed to the annual value of $26.2 million for FY2024, which is 2864.57% down from last year.
- According to the latest figures from Q3 2025, Taysha Gene Therapies' Total Current Liabilities is $28.6 million, which was down 239.99% from $25.3 million recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Total Current Liabilities peaked at $180.5 million during Q3 2023, and registered a low of $22.6 million during Q1 2025.
- Over the past 4 years, Taysha Gene Therapies' median Total Current Liabilities value was $36.8 million (recorded in 2023), while the average stood at $47.6 million.
- In the last 5 years, Taysha Gene Therapies' Total Current Liabilities soared by 44452.76% in 2023 and then crashed by 8374.35% in 2024.
- Taysha Gene Therapies' Total Current Liabilities (Quarter) stood at $62.8 million in 2022, then crashed by 41.46% to $36.8 million in 2023, then decreased by 28.65% to $26.2 million in 2024, then grew by 9.17% to $28.6 million in 2025.
- Its Total Current Liabilities stands at $28.6 million for Q3 2025, versus $25.3 million for Q2 2025 and $22.6 million for Q1 2025.